Αποτελέσματα Αναζήτησης
1 Αυγ 2016 · In theory, inhaled insulin completely eliminated the psychological barriers associated with subcutaneous insulin delivery, such as needle phobia and incorrect injection technique. However, in October 2007, Pfizer withdrew Exubera from the market, and in January 2016, Sanofi withdrew from a $925 million marketing agreement with MannKind for ...
28 Δεκ 2022 · Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes.
25 Δεκ 2023 · Exubera is a rapid-acting form of human insulin that is inhaled through the mouth. It works by lowering levels of glucose (sugar) in the blood. Exubera is used to treat type 1 (insulin dependent) or type 2 (non-insulin dependent) diabetes in adults.
Exubera, developed by Inhale Therapeutics (later named Nektar Therapeutics), became the first inhaled insulin product to be marketed, in 2006 by Pfizer, [3] but poor sales led Pfizer to withdraw it in 2007. [4]
17 Σεπ 2007 · Exubera is the first inhaled form of insulin and the first insulin option to be available in the U.S., United Kingdom, Germany, Ireland, Greece, Spain, Mexico, Brazil, Sweden and UAE in 85 years that does not need to be administered by injection.
1 Οκτ 2004 · A study in healthy subjects showed inhaled insulin to have a rapid onset of action that was significantly faster than regular insulin and a duration of action between that of insulin lispro and regular insulin.
13 Αυγ 2019 · Patients eligible to take EXU per approved local label were randomized to EXU or routine care and followed per usual care, with scheduled FEV 1 tests at baseline, 6 months, and yearly. Randomization halted in October 2007 after Pfizer announced it would stop marketing EXU due to low sales.
